Genome editing, a next step in genetic therapy, corrects hemophilia in animals

June 26, 2011

Using an innovative gene therapy technique called genome editing that hones in on the precise location of mutated DNA, scientists have treated the blood clotting disorder hemophilia in mice. This is the first time that genome editing, which precisely targets and repairs a genetic defect, has been done in a living animal and achieved clinically meaningful results.

As such, it represents an important step forward in the decades-long scientific progression of gene therapy -- developing treatments by correcting a disease-causing DNA sequence. In this new study, researchers used two versions of a genetically engineered virus (adeno-associated virus, or AAV) -- one carrying enzymes that cut DNA in an exact spot and one carrying a replacement gene to be copied into the DNA sequence. All of this occurred in the of living mice.

"Our research raises the possibility that genome editing can correct a at a clinically meaningful level after in vivo delivery of the nucleases," said the study leader, Katherine A. High, M.D., a hematologist and gene therapy expert at The Children's Hospital of Philadelphia. High, a Howard Hughes Medical Institute Investigator, directs the Center for Cellular and at Children's Hospital, and has investigated gene therapy for hemophilia for more than a decade.

The study appeared online today in Nature.

High's research, a collaboration with scientists at Sangamo BioSciences, Inc., makes use of genetically engineered enzymes called zinc finger nucleases (ZFNs) that act as molecular word processors, editing mutated sequences of DNA. Scientists have learned how to design ZFNs custom-matched to a specific gene location. ZFNs specific for the factor 9 gene (F9) were designed and used in conjunction with a DNA sequence that restored normal gene function lost in hemophilia.

By precisely targeting a specific site along a chromosome, ZFNs have an advantage over conventional gene therapy techniques that may randomly deliver a replacement gene into an unfavorable location, bypassing normal biological regulatory components controlling the gene. This imprecise targeting carries a risk of "insertional mutagenesis," in which the corrective gene causes an unexpected alteration, such as triggering leukemia.

In hemophilia, an inherited single-gene mutation impairs a patient's ability to produce a blood-clotting protein, leading to spontaneous, sometimes life-threatening bleeding episodes. The two major forms of the disease, which occurs almost solely in males, are hemophilia A and hemophilia B, caused respectively by a lack of clotting factor VIII and clotting factor IX. Patients are treated with frequent infusions of clotting proteins, which are expensive and sometimes stimulate the body to produce antibodies that negate the benefits of treatment.

In the current study, the researchers used genetic engineering to produce mice with hemophilia B, modeling the disease in people. Before treatment, the mice had no detectable levels of clotting factor IX.

Previous studies by other researchers had shown that ZFNs could accomplish genome editing in cultured stem cells that were then injected into mice to treat sickle cell disease. However, this ex vivo approach is not feasible for many human genetic diseases, which affect whole organ systems. Therefore the current study tested whether genome editing was effective when directly performed in vivo (in a living animal).

High and colleagues designed two versions of a vector, or gene delivery vehicle, using adeno-associated virus (AAV). One AAV vector carried ZFNs to perform the editing, the other delivered a correctly functioning version of the F9 gene. Because different mutations in the same gene may cause hemophilia, the process replaced seven different coding sequences, covering 95 percent of the disease-carrying mutations in hemophilia B.

The researchers injected mice with the gene therapy vector, which was designed to travel to the liver—where clotting factors are produced. The mice that received the ZFN/gene combination then produced enough clotting factor to reduce blood clotting times to nearly normal levels. Control mice receiving vectors lacking the ZFNs or the F9 minigene had no significant improvements in circulating factor or in clotting times.

The improvements persisted over the eight months of the study, and showed no toxic effects on growth, weight gain or liver function, clues that the treatment was well-tolerated.

"We established a proof of concept that we can perform genome editing in vivo, to produce stable and clinically meaningful results," said High. "We need to perform further studies to translate this finding into safe, effective treatments for hemophilia and other single-gene diseases in humans, but this is a promising strategy for ." She continued, "The clinical translation of genetic therapies from mouse models to humans has been a lengthy process, nearly two decades, but we are now seeing positive results in a range of diseases from inherited retinal disorders to hemophilia. In vivo genome editing will require time to mature as a therapeutic, but it represents the next goal in the development of genetic therapies."

Explore further: Genome editing: Efficient CRISPR experiments in mouse cells

More information: "In vivo genome editing restores hemostasis in a mouse model of hemophilia," Nature, published online June 26, 2011. doi: 10.1038/nature10177

Related Stories

Genome editing: Efficient CRISPR experiments in mouse cells

October 25, 2016

In order to use the CRISPR-Cas9 system to cut genes, researchers must design an RNA sequence that matches the DNA of the target gene. Most genes have hundreds of such sequences, with varying activity and uniqueness in the ...

Researchers use CRISPR to accelerate search for HIV cure

October 25, 2016

Researchers at UC San Francisco and the academically affiliated Gladstone Institutes have used a newly developed gene-editing system to find gene mutations that make human immune cells resistant to HIV infection.

Genome engineering paves the way for sickle cell cure

October 12, 2016

A team of physicians and laboratory scientists has taken a key step toward a cure for sickle cell disease, using CRISPR-Cas9 gene editing to fix the mutated gene responsible for the disease in stem cells from the blood of ...

Recommended for you

How Frankenstein saved humankind from probable extinction

October 28, 2016

Frankenstein as we know him, the grotesque monster that was created through a weird science experiment, is actually a nameless Creature created by scientist Victor Frankenstein in Mary Shelley's 1818 novel, "Frankenstein." ...

Closer look reveals tubule structure of endoplasmic reticulum

October 28, 2016

(—A team of researchers from the U.S. and the U.K. has used high-resolution imaging techniques to get a closer look at the endoplasmic reticulum (ET), a cellular organelle, and in so doing, has found that its structure ...

Computer model is 'crystal ball' for E. coli bacteria

October 28, 2016

It's difficult to make predictions, especially about the future, and even more so when they involve the reactions of living cells—huge numbers of genes, proteins and enzymes, embedded in complex pathways and feedback loops. ...


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Jun 26, 2011
And they can just create large enough numbers of the vehicles just through self assembly? That would make it quick to make them without any of the destructive effects of a reproducing virus on the cell, right? You could actually change genes in a fully formed adult organism. You could sequence various tissues and organs to look for age related mutations and correct them. Combined with telomere research you could really see real anti-aging/reverse-aging therapy.
not rated yet Jun 27, 2011
TCP/IP Viral Packet delivery method nice, but this suffers a major problem.

1rst viral vector packet x% chance of immune reaction
2nd viral vector packet same x% of immune reaction
3rd ...

O-ring failure of Challenger was downed by similar results

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.